Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infection

Ramos-Casals, Manuel; Civita, L. La; Vita, Salvatore De; Solans, Roser; Luppi, Mario; Medina, Francisco J.; Caramaschi, Paola; Fadda, P.; Marchi, G. De; López‐Guillermo, Armando; Font, Josep

doi:10.1002/art.22476

Cited by 70 publications

(46 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, the efficacy of rituximab for treatment of lymphoproliferative disorders among HCV-positive patients was documented (74)(75)(76)(77)(78)(79)(80)(81)(82)(83)(84)(85). The most relevant studies on rituximab treatment of HCV-associated lymphoproliferative disorders are reported in Table V.…”

Section: Treatment Of Hcv-associated Lymphoproliferative Disordersmentioning

confidence: 99%

Extrahepatic disorders of HCV infection: A distinct entity of B-cell neoplasia?

et al. 2010

View full text Add to dashboard Cite

Abstract. Some infectious agents have been associated with B-cell lymphoma development. In the last decades, it has been demonstrated that patients infected by hepatitis C virus (HCV) are more likely to develop B-cell non-Hodgkin's lymphoma (NHL) than those uninfected. The prevalence of HCV-infection among NHL patients is reported in this review of all Italian studies on NHL and HCV infection, both case-control and case series. From 18 studies, the prevalence of anti-HCV antibodies in 2736 NHL patients was 19.7% (range: 8.3-37.1%). The association of HCV-infection with each NHL histotype in case-control studies is discussed. Molecular mechanisms by which HCV infection promotes B-cell NHL development is also explored and indicate that HCV-associated lymphomas may be a distinct entity. Clarification of these mechanisms may improve diagnosis, classification and therapy of this subset of NHL. Finally, treatment of HCV-positive patients with lymphoproliferative disorders are herein summarized and further support the notion that HCV infection contributes to the development of these pathologic conditions.

show abstract

Section: Treatment Of Hcv-associated Lymphoproliferative Disordersmentioning

confidence: 99%

Extrahepatic disorders of HCV infection: A distinct entity of B-cell neoplasia?

et al. 2010

View full text Add to dashboard Cite

show abstract

“…For example, Somer et al observed that after rituximab treatment a patient with Sjogren's syndrome (SS) and lymphoma showed improvement of parotidomegaly, ocular tests and salivary flow rate [139] . In addition, Ramos-Casals et al reported two patients with HCV-related SS who developed B-cell lymphoma and who responded successfully to treatment with rituximab [140] . In synthesis, in spite of the limited number of described cases, it appears reasonable to consider rituximab as a safe and effective therapy for HCV-related indolent B-cell lymphoma.…”

Section: Lymphomamentioning

confidence: 99%

Hepatitis C virus-related lymphoproliferative disorders: An overview

Zignego

Giannini²,

Ferri³

2007

WJG

109

106

View full text Add to dashboard Cite

Hepatitis C virus (HCV) is a global health problem affecting 3% of the world's population (about 180 million) and a cause of both hepatic and extrahepatic diseases. B-cell lymphoproliferative disorders, whose prototype is mixed cryoglobulinemia, represent the most closely related as well as the most investigated HCVrelated extrahepatic disorder. The association between extrahepatic (lymphoma) as well as hepatic malignancies (hepatocellular carcinoma) has justified the inclusion of HCV among human cancer viruses. HCV-associated manifestations also include porphyria cutanea tarda, lichen planus, nephropathies, thyreopathies, sicca syndrome, idiopathic pulmonary fibrosis, diabetes, chronic polyarthritis, sexual dysfunctions, cardiopathy/ atherosclerosis, and psychopathological disorders. A pathogenetic link between HCV virus and some lymphoproliferative disorders was confirmed by their responsiveness to antiviral therapy, which is now considered the first choice treatment. The aim of the present paper is to provide an overview of extrahepatic manifestations of HCV infection with particular attention to B-cell lymphoproliferative disorders. Available pathogenetic hypotheses and suggestions about the most appropriate, currently available, therapeutic approaches will also be discussed.

show abstract

“…It should be also noted that approximately half of the patients with HCV-associated sialadenitis have circulating cryoglobulins and low complement levels (compared to ∼10 % of patients with primary Sjögren's syndrome) and approximately 20 % clinical manifestations of vasculitis (compared to 12 % of patients with primary Sjögren's) [6], emphasizing that in a significant proportion of patients sialadenitis is part of the HCV-related mixed cryoglobulinemia syndrome. Such patients with cryoglobulinemia and sialadenitis run a higher risk for development of lymphoma either in the salivary glands or the liver [8]. Whether or not HCV is directly (through viral replication in the salivary glands) or indirectly involved to the development of sialadenitis has not been clearly determined so far [5].…”

Section: Clinical Featuresmentioning

confidence: 99%

HCV Treatments and Their Integration Into Rheumatology

Vassilopoulos

Calabrese

2015

Curr Rheumatol Rep

View full text Add to dashboard Cite

Hepatitis C virus (HCV) has been associated with distinct rheumatic syndromes including arthritis, sialadenitis, and cryoglobulinemic vasculitis (CV). The therapy of these HCV-associated syndromes includes antiviral therapy with or without the addition of immunosuppressives while clinical response is mainly seen in patients who clear the virus after antiviral therapy. Despite significant therapeutic advances, existing antiviral therapies with interferon-a (IFNa)-based schemes achieve viral eradication only in approximately half the patients. Recently, oral antivirals that target specific HCV proteins referred as direct acting antivirals (DAAs) have been developed and approved. Short-term (12-24 weeks) combination schemes with or without IFN ("IFN-free" regimens) including these inhibitors clear the virus in more than 90 % of treated patients. Here, we review current therapeutic options in HCV-associated rheumatic syndromes and the potential role of the newly available antivirals in an integrated therapeutic approach.

show abstract

Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infection

Cited by 70 publications

References 47 publications

Extrahepatic disorders of HCV infection: A distinct entity of B-cell neoplasia?

Extrahepatic disorders of HCV infection: A distinct entity of B-cell neoplasia?

Hepatitis C virus-related lymphoproliferative disorders: An overview

HCV Treatments and Their Integration Into Rheumatology

Contact Info

Product

Resources

About